Showing 1 - 4 results of 4 for search 'D. L. Stroyakovskiy', query time: 0.02s
Refine Results
-
1
Ramucirumab with paclitaxel or FOLFIRI as second-line treatment in docetaxel-pre-treated patients with metastatic gastric cancer in real-world setting by N. S. Besova, Т. А. Titova, А. А. Tryakin, Е. V. Artamonova, Е. S. Obarevich, D. L. Stroyakovskiy, О. Е. Kalinin, I. S. Stilidi
Published 2021-06-01
Article -
2
Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia by N. S. Besova, T. A. Titova, E. V. Artamonova, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukal’chuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, A. A. Tryakin, I. S. Stilidi
Published 2019-12-01
Article -
3
Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA t... by N. S. Besova, T. A. Titova, Е. V. Artamonova, A. A. Tryakin, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukalchuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, I. S. Stilidi
Published 2020-07-01
Article -
4
Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia by M. Yu. Fedyanin, К M. Ehlsnukaeva, I. A. Demidova, D. L. Stroyakovskiy, Yu. A. Shelygin, А. S. Tsukanov, М. V. Panina, V. Р. Shubin, F. V. Moiseenko, E. Yu. Karpenko, L. V. Bolotina, A. V. Kudryavtseva, М. L. Filipenko, I. P. Oskorbin, L. Yu. Vladimirova, N. N. Timoshkina, О. I. Kit, А. М. Stroganova, S. L. Dranko, А. I. Senderovich, А. А. Tryakin, S. А. Tjulandin
Published 2021-06-01
Article